BR112018072190A2 - isoquinolin-3-il carboxamidas e preparação e uso das mesmas - Google Patents

isoquinolin-3-il carboxamidas e preparação e uso das mesmas

Info

Publication number
BR112018072190A2
BR112018072190A2 BR112018072190-5A BR112018072190A BR112018072190A2 BR 112018072190 A2 BR112018072190 A2 BR 112018072190A2 BR 112018072190 A BR112018072190 A BR 112018072190A BR 112018072190 A2 BR112018072190 A2 BR 112018072190A2
Authority
BR
Brazil
Prior art keywords
treatment
signaling pathway
wnt signaling
diseases
disorders
Prior art date
Application number
BR112018072190-5A
Other languages
English (en)
Inventor
Kumar Kc Sunil
Kumar Mittapalli Gopi
Joseph HOFILENA Brian
Timothy Marakovits Joseph
Chiruta Chandramouli
Ching Mak Chi
Cao Jianguo
Original Assignee
Samumed, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samumed, Llc filed Critical Samumed, Llc
Publication of BR112018072190A2 publication Critical patent/BR112018072190A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

os compostos de isoquinolina para o tratamento de várias doenças e patologias são divulgados. mais particularmente, a presente divulgação refere-se ao uso de um composto de isoquinolina ou seus análogos no tratamento de distúrbios caracterizados pela ativação da via de sinalização wnt (por exemplo, câncer, proliferação celular anormal, angiogênese, doença de alzheimer, doença pulmonar, inflamação, doenças autoimunes e osteoartrite), pela modulação de eventos celulares mediados pela via de sinalização wnt, bem como condições/distúrbios/doenças neurológicas ligadas à superexpressão de dyrk1a.
BR112018072190-5A 2016-04-27 2017-04-27 isoquinolin-3-il carboxamidas e preparação e uso das mesmas BR112018072190A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662328210P 2016-04-27 2016-04-27
US62/328,210 2016-04-27
PCT/US2017/029797 WO2017189823A2 (en) 2016-04-27 2017-04-27 Isoquinolin-3-yl carboxamides and preparation and use thereof

Publications (1)

Publication Number Publication Date
BR112018072190A2 true BR112018072190A2 (pt) 2019-02-12

Family

ID=60157342

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018072190-5A BR112018072190A2 (pt) 2016-04-27 2017-04-27 isoquinolin-3-il carboxamidas e preparação e uso das mesmas

Country Status (19)

Country Link
US (5) US10508099B2 (pt)
EP (2) EP3943086A1 (pt)
JP (1) JP7023243B2 (pt)
KR (1) KR102399206B1 (pt)
CN (1) CN109311819B (pt)
AR (1) AR108326A1 (pt)
AU (1) AU2017258187B2 (pt)
BR (1) BR112018072190A2 (pt)
CA (1) CA3022044A1 (pt)
CL (2) CL2018003050A1 (pt)
CO (1) CO2018012655A2 (pt)
IL (1) IL262495B (pt)
MA (1) MA43605B1 (pt)
MX (1) MX2018013173A (pt)
PE (1) PE20190260A1 (pt)
PH (1) PH12018502259A1 (pt)
RU (1) RU2018141379A (pt)
SG (2) SG11201809310PA (pt)
WO (1) WO2017189823A2 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2935222T3 (en) 2012-12-21 2019-01-07 Epizyme Inc PRMT5 INHIBITORS AND APPLICATIONS THEREOF
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
TW201803869A (zh) 2016-04-27 2018-02-01 健生藥品公司 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑
MA48994A (fr) 2017-03-30 2020-02-05 Hoffmann La Roche Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
JP2020537667A (ja) * 2017-10-17 2020-12-24 ヴァンダービルト ユニバーシティー ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
US10604514B2 (en) * 2017-10-19 2020-03-31 Samumed, Llc 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof
US10413537B2 (en) 2017-10-27 2019-09-17 Samumed, Llc 6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof
WO2019084497A1 (en) 2017-10-27 2019-05-02 Samumed, Llc 6- (HETEROARYL AND ARYL WITH 6 CHAINS) ISOQUINOLIN-3-YL CARBOXAMIDES, THEIR PREPARATION AND THEIR USE
WO2019089835A1 (en) * 2017-10-31 2019-05-09 Samumed, Llc Diazanaphthalen-3-yl carboxamides and preparation and use thereof
CN112292183A (zh) 2018-06-18 2021-01-29 詹森药业有限公司 作为RORγt的调节剂的6-氨基吡啶-3-基吡唑
CA3103932A1 (en) 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv Pyridinyl pyrazoles as modulators of roryt
WO2019243999A1 (en) 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv Phenyl substituted pyrazoles as modulators of roryt
US11345666B2 (en) 2018-06-18 2022-05-31 Janssen Pharmaceutica Nv Phenyl and pyridinyl substituted imidazoles as modulators of RORγT
TW202024053A (zh) * 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
WO2021004547A1 (en) * 2019-07-11 2021-01-14 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as inhibitors of hpk1
CN114401946A (zh) * 2019-09-05 2022-04-26 鲁南制药集团股份有限公司 Magl抑制剂及其制备方法、用途
US20230406844A1 (en) * 2020-10-29 2023-12-21 Merck Sharp & Dohme Llc N-linked isoquinoline amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
KR20230157981A (ko) * 2021-02-19 2023-11-17 칼비스타 파마슈티컬즈 리미티드 인자 xiia 저해제
WO2023055679A1 (en) * 2021-10-01 2023-04-06 Merck Sharp & Dohme Llc C-linked isoquinoline amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
WO2023107714A2 (en) * 2021-12-10 2023-06-15 Prothena Biosciences Limited Methods for treating neurological disorders

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4164559A (en) 1977-09-21 1979-08-14 Cornell Research Foundation, Inc. Collagen drug delivery device
US4474752A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
ES2131463B1 (es) * 1997-04-08 2000-03-01 Lilly Sa Derivados de ciclopropilglicina con propiedades farmaceuticas.
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
US6440102B1 (en) 1998-07-23 2002-08-27 Durect Corporation Fluid transfer and diagnostic system for treating the inner ear
DE19853299C2 (de) 1998-11-19 2003-04-03 Thomas Lenarz Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs
US6120484A (en) 1999-02-17 2000-09-19 Silverstein; Herbert Otological implant for delivery of medicament and method of using same
US6967023B1 (en) 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
US6648873B2 (en) 2001-09-21 2003-11-18 Durect Corp. Aural catheter system including anchor balloon and balloon inflation device
GB0310867D0 (en) 2003-05-12 2003-06-18 Novartis Ag Organic compounds
US7008953B2 (en) 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
EP1861161A4 (en) 2005-01-24 2012-05-16 Neurosystec Corp APPARATUS AND METHOD FOR DISPENSING THERAPEUTIC AND / OR OTHER AGENTS IN THE INTERNAL EAR AND OTHER FABRICS
US7998978B2 (en) * 2006-05-01 2011-08-16 Pfizer Inc. Substituted 2-amino-fused heterocyclic compounds
CA2696321A1 (en) * 2007-08-15 2009-02-19 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
CA2770320A1 (en) 2009-08-10 2011-02-17 Epitherix, Llc Indazoles as wnt/b-catenin signaling pathway inhibitors and therapeutic uses thereof
US8252812B2 (en) 2009-08-10 2012-08-28 Samumed, Llc Indazole inhibitors of the WNT signal pathway and therapeutic uses thereof
KR20130012072A (ko) 2010-03-31 2013-01-31 액테리온 파마슈티칼 리미티드 항박테리아성 이소퀴놀린-３-일우레아 유도체
MA34836B1 (fr) 2010-12-17 2014-01-02 Hoffmann La Roche Composes heterocycliques azotes 6;6- condenses substitues et leurs utilisations
EP3473099A1 (en) 2011-09-14 2019-04-24 Samumed, LLC Indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors
WO2013169793A2 (en) * 2012-05-09 2013-11-14 Ipierian, Inc. Methods and compositions for tdp-43 proteinopathies
US9557993B2 (en) 2012-10-23 2017-01-31 Analog Devices Global Processor architecture and method for simplifying programming single instruction, multiple data within a register
EP3119393A4 (en) 2014-03-20 2018-02-28 Samumed, LLC 5-substituted indazole-3-carboxamides and preparation and use thereof
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
EP3813826A4 (en) 2018-06-26 2022-07-06 BioSplice Therapeutics, Inc. METHOD OF TREATMENT OF CANCER USING A CLK INHIBITOR

Also Published As

Publication number Publication date
CO2018012655A2 (es) 2019-04-30
AU2017258187A1 (en) 2018-11-15
EP3448838B1 (en) 2021-08-11
MA43605A1 (fr) 2020-04-30
JP2019515931A (ja) 2019-06-13
WO2017189823A3 (en) 2018-02-08
AU2017258187B2 (en) 2021-08-26
MX2018013173A (es) 2019-02-13
PE20190260A1 (es) 2019-02-25
US10287267B2 (en) 2019-05-14
US20180222887A1 (en) 2018-08-09
JP7023243B2 (ja) 2022-02-21
AR108326A1 (es) 2018-08-08
PH12018502259A1 (en) 2019-06-10
IL262495B (en) 2021-12-01
CA3022044A1 (en) 2017-11-02
EP3448838A2 (en) 2019-03-06
MA43605B1 (fr) 2020-10-28
EP3943086A1 (en) 2022-01-26
SG10201914127PA (en) 2020-02-27
IL262495A (en) 2018-12-31
US20170313681A1 (en) 2017-11-02
EP3448838A4 (en) 2019-12-25
SG11201809310PA (en) 2018-11-29
US10556885B2 (en) 2020-02-11
RU2018141379A3 (pt) 2020-08-13
US10508099B2 (en) 2019-12-17
US11174244B2 (en) 2021-11-16
KR102399206B1 (ko) 2022-05-17
CL2019002067A1 (es) 2020-07-10
CL2018003050A1 (es) 2019-01-25
US20180208580A1 (en) 2018-07-26
KR20190012167A (ko) 2019-02-08
US20200339536A1 (en) 2020-10-29
CN109311819A (zh) 2019-02-05
WO2017189823A2 (en) 2017-11-02
US11673881B2 (en) 2023-06-13
CN109311819B (zh) 2022-10-25
US20230104155A1 (en) 2023-04-06
RU2018141379A (ru) 2020-05-28

Similar Documents

Publication Publication Date Title
BR112018072190A2 (pt) isoquinolin-3-il carboxamidas e preparação e uso das mesmas
PH12016501835A1 (en) 5-substituted indazole -3- carboxamides and preparation and use thereof
PH12018502258A1 (en) Isoquinolin-3-yl carboxamides and preparation and use thereof
WO2015042078A3 (en) Substituted aminopyrimidine compounds and methods of use
CO7230336A2 (es) Inhibidores de indazol de la ruta de señalización de wnt y usos terapeúticos de los mismos
BR112015020998A2 (pt) compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios
BR112017012588B8 (pt) Compostos heteroaril-heteroarila bicíclicos de ácido benzoico, seus usos, composições farmacêuticas, métodos de preparação destas e métodos para provocar ou promover o desenvolvimento de neuritos, o crescimento de neuritos e/ou a regeneração de neuritos e para ativar o receptor beta do ácido retinoico
EA202092002A1 (ru) 5-гетероарилзамещенные индазол-3-карбоксамиды и их получение и применение
TN2016000107A1 (en) Substituted phenylalanine derivatives
CL2021002483A1 (es) Compuestos y composiciones como moduladores de la señalización tlr
BR112017024714A2 (pt) métodos para preparação do fator de von willebrand modificado
MD4793C1 (ro) Noi compuşi de izoindolină sau izochinolină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin
MX2020009566A (es) Compuestos como moduladores de la se?alizacion de tlr2.
BR112017017704A2 (pt) derivados de 2-aminopiridina como antagonistas do receptor de adenosina a2b e ligantes dos receptores de melatonina mt3
WO2014141169A3 (en) Novel anti-neurodegenerative natural compounds isolated from alpiniae oxyphyllae fructus and total synthesis theirof
BR112018072588A2 (pt) composto, composição farmacêutica, e, uso do composto.
BR112016002872A2 (pt) derivados de 1 h-pirazolo[3,4-b]piridina e composições farmacêuticas dos mesmos para o tratamento de distúrbios proliferativos
GB2553686A (en) Ethynylxanthines, preparation and use as calcium ion channel modulators
WO2019004970A3 (en) HETEROBIVALENT LIGANDS THAT CAN BE USED IN THE TREATMENT OF PARKINSON'S DISEASE
MA37780A1 (fr) Nouveaux acides 5-aminotétrahydrochinolino-2-carboxyliques et leur utilisation
BR112015026533A2 (pt) tratamento ou prevenção das desordens do autismo com o uso de mentol, linalol e/ou icilina
EA201690240A1 (ru) Новые соединения индазола и способ их получения

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2772 DE 20/02/2024.